Specify a stock or a cryptocurrency in the search bar to get a summary
Fennec Pharmaceuticals Inc
FENCFennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. Address: 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709
Analytics
WallStreet Target Price
16.17 USDP/E ratio
–Dividend Yield
1.98 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures FENC
Dividend Analytics FENC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History FENC
Stock Valuation FENC
Financials FENC
Results | 2019 | Dynamics |